Bioceltix Valuation Multiples

Bioceltix Overview

About Bioceltix

Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.

Founded

N/A

HQ

Employees

N/A

Website

bioceltix.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($4M)

EV

$111M

Valuation Multiples

Multiples.vc

Start free trial

Bioceltix Financials

Bioceltix reported last 12-month revenue of — and negative EBITDA of ($4M).

In the same LTM period, Bioceltix generated ($4M) in EBITDA losses and had net loss of ($4M).

Bioceltix P&L

In the most recent fiscal year, Bioceltix reported revenue of — and EBITDA of ($4M).

Bioceltix expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bioceltix Stock Performance

Bioceltix has current market cap of $117M, and enterprise value of $111M.

Bioceltix's stock price is $21.22.

Bioceltix Valuation Multiples

Bioceltix trades at (31.3x) EV/EBITDA.

Bioceltix Financial Valuation Multiples

As of March 21, 2026, Bioceltix has market cap of $117M and EV of $111M.

Equity research analysts estimate Bioceltix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bioceltix has a P/E ratio of (31.6x).

Bioceltix Margins & Growth Rates

Bioceltix's revenue in the last fiscal year grew by —.

Bioceltix Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Bioceltix M&A Activity

Bioceltix acquired XXX companies to date.

Last acquisition by Bioceltix was on XXXXXXXX, XXXXX. Bioceltix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bioceltix Investment Activity

Bioceltix invested in XXX companies to date.

Bioceltix made its latest investment on XXXXXXXX, XXXXX. Bioceltix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).